About STI Pharma

a specialty pharmaceutical company

founded in

2008

Who we are and what we do

A Little About Us

Founded in 2008 by Anup Dam, a seasoned industry executive, STI PHARMA is a privately owned, specialty pharmaceutical company focused on the acquisition, development, licensing and commercialization of generic drugs with a strategic focus on injectables. We are committed to developing high quality injectables designed to meet evolving patient needs. With our well-established relationships with US FDA approved contract manufacturers, we strive to ensure an uninterupted supply of our products to our customers.

A Brief History

STI Milestone Events

2008
Our begining

STI Pharma, located in Newtown, PA, was founded in 2008 by a team of industry veterans.

2008 to 2013
Acquired 6 Products

Acquired 6 generic products (ANDAs) from a global generic pharmaceutical company. Launched Dexamethasone Elixir, Betamethasone Valerate Lotion, Sulfatrim Suspension and Escitalopram Tablets

2013
Logistics

Contracted with a 3rd party logistics provider (3PL) to provide warehousing, shipping and accounting services for STI’s products. During this time STIi initiated label and marketing capabilities.

2015
Transition to Injectable Products

STI Began transitioning its focus to developing injectable products.

2016 to 2018
Injectable Development

Developed 6 generic injectables products, transitioned the products to manufacturing sites. STI submitted and managed the injectable dossiers with the FDA to approval.

2017
R&D Lab Built

Built R&D laboratories dedicated to formulation development and analytical services

2018
Launched Cyclophosphamide

Launched Cyclophosphamide (1st Oncology product).

2019
Frank Mullery joins STI

Frank Mullery joins STI as President and CCO.

2019
FDA Approvals of Carmustine and Arsenic Trioxide

FDA Approval of Carmustine (1st injectable product). FDA Approval of Arsenic Trioxide (2nd injectable product).

2020
Commercial Launch of Carmustine and FDA Approval of Thiotepa

Commercial launch of Carmustine and FDA approval of Thiotepa (3rd injectable product)

2020 to 2021
3 Product Launches and Expanded Pipeline

Launch of Thiotepa, Arsenic Trioxide and Succinylcholine (1st Commercial License). Expanded pipeline to include 12+ injectable products ranging from oncology to complex peptides

MEET THE TEAM

industry experts

Anup Dam
Chairman & Manager
Frank Mullery
President and Chief Commercial Officer
Michael Stalhamer
VP Regulatory Affairs & Product Development
Stephanie Herman
Head of Finance